COPD Management
On this page
Direct answer
GOLD ABE grouping now drives chronic obstructive pulmonary disease therapy: a post-bronchodilator FEV1/FVC below 0.7 confirms the diagnosis, exacerbation history separates group E (two or more moderate exacerbations or one hospitalisation) from group A and B, and initial treatment is a long-acting muscarinic antagonist plus long-acting beta-agonist for groups B and E — with an inhaled corticosteroid added only when blood eosinophils are 300 or more, or around 100–300 with frequent exacerbations or an asthmatic history. Smoking cessation is the only intervention that slows the decline in lung function. An exacerbation gets bronchodilators, 40 mg of prednisolone for five days, antibiotics when sputum purulence increases, oxygen titrated to 88–92 per cent, and non-invasive ventilation once pH falls below 7.35 with a PaCO2 above 45 mmHg — the single biggest mortality reducer in the whole topic.
What you must remember
- Diagnosis: spirometry is mandatory — post-bronchodilator FEV1/FVC below 0.7; GOLD spirometric grades 1–4 follow the per cent-predicted FEV1 but no longer drive drug choice.
- ABE grouping: 0 or 1 moderate exacerbation, not leading to hospitalisation = group A (mMRC 0–1) or B (mMRC 2 or more); 2 or more moderate, or 1 hospitalisation = group E, regardless of symptoms.
- Inhaled therapy: LABA-LAMA is the initial choice for groups B and E; add an inhaled corticosteroid when eosinophils are 300 or more, or 100–300 with exacerbations or an asthma component — triple therapy for group E with high eosinophils.
- Why ICS is rationed: pneumonia risk, and in Indian practice a recognised increased risk of tuberculosis — withdrawal is advised when pneumonia or mycobacterial infection occurs.
- Exacerbation protocol: salbutamol plus ipratropium, prednisolone 40 mg for 5 days (the REDUCE trial showed 5 days equals 14), and antibiotics — amoxicillin-clavulanate, doxycycline or a macrolide — when sputum purulence increases or the case is severe.
- Oxygen and NIV: target saturation 88–92 per cent in carbon-dioxide retainers; start bilevel NIV for pH below 7.35 with PaCO2 above 45 mmHg despite optimal medical therapy.
- Prevention: annual influenza and pneumococcal vaccination plus COVID-19 vaccination; prophylactic azithromycin 250 mg alternate days or thrice weekly in selected frequent exacerbators after excluding tuberculosis.
- Advanced options: long-term oxygen therapy for PaO2 at or below 55 mmHg (or 56–59 with cor pulmonale or polycythaemia), lung volume reduction for upper-lobe emphysema and low exercise capacity, pulmonary rehabilitation after an admission, and home NIV for chronic hypercapnia.
How to work through a stable-clinic case
A 64-year-old ex-smoker of 40 pack-years has an mMRC dyspnoea grade of 2, one exacerbation last year treated with oral steroids at home, FEV1 48 per cent predicted and blood eosinophils of 120. First fix the diagnosis: post-bronchodilator FEV1/FVC of 0.52 — COPD, GOLD grade 3 (moderate-to-severe airflow limitation). Second, group him: two or more moderate exacerbations or one hospitalisation would make him E; with a single moderate event and mMRC 2, he is group B. Third, prescribe: LABA-LAMA — say umeclidinium-vilanterol — and enroll him in vaccination and rehabilitation. Fourth, weigh the eosinophil: at 120 with only one exacerbation, hold the inhaled corticosteroid; if next year he is admitted twice, his eosinophils re-enter the argument. Now change one variable: had his eosinophils been 420, the answer is triple therapy from the start; had his pH been 7.28 in casualty with a PaCO2 of 68, the answer is NIV within the first hour after controlled oxygen, bronchodilators and steroids. Same disease, three different question papers.
Where students slip
The examination loves leftovers from older editions. Writing "ICS-LABA for all" scores nothing — ABE retired symptom-driven escalation for the B and E groups. Prescribing long-term oxygen for a PaCO2 of 55 with normal PaO2 is wrong; the PaO2 threshold is what counts. Giving 14 days of steroids ignores the REDUCE evidence, and missing the 88–92 per cent oxygen target — or the Indian tendency to run wall oxygen at full flow into a retainer — is precisely the avoidable death the examiner has in mind.
Frequently asked questions
Which spirometric criterion diagnoses COPD?
A post-bronchodilator FEV1/FVC ratio below 0.7; the FEV1 per cent predicted then assigns GOLD grades 1–4.
What is first-line inhaler therapy for group E COPD?
A long-acting muscarinic antagonist plus long-acting beta-agonist, adding an inhaled corticosteroid when eosinophils are 300 or more.
How long should oral steroids run in an exacerbation?
Prednisolone 40 mg daily for five days — non-inferior to longer courses and with fewer side effects.
When does an exacerbation need NIV?
When pH is below 7.35 and PaCO2 above 45 mmHg despite controlled oxygen and medical therapy, provided the patient can protect the airway.
Why is chronic azithromycin used cautiously in India?
Prophylactic macrolides reduce exacerbations but carry QT prolongation, hearing effects and resistance concerns — and tuberculosis must be excluded first.